GENFIT Stock: New Five-Year Record After a Surge of Over 115% in Three Months
GENFIT reaches a new milestone this Thursday, February 19, hitting a high since the April 2020 drop during the Covid crisis. The Lille-based biotech's stock advanced 3.56% from the previous day, showcasing a spectacular upward trajectory over the past several weeks. The announcement of the annual 2025 revenue, scheduled for February 26, is the next major event for the stock.
Current Performance
GENFIT's stock price surpassed its previous peak of 8.115 euros reached the day before, bringing the stock to 8.145 euros. Over the past week, the increase amounts to 21.21%, while the quarterly performance exceeds 115%. This dynamic places the stock well above its reference moving averages: the MM50 is established at 5.62 euros and the MM200 at 4.12 euros, indicating a significant gap that reflects the magnitude of the recent bullish movement. The RSI, an indicator measuring the speed and intensity of price changes, stands at 82, well above the threshold of 70 generally associated with an overbought zone. This level indicates that buying pressure has been particularly strong in recent sessions. Moreover, the price is now above the upper Bollinger band, set at 7.97 euros, confirming that the stock is in statistically extreme territory relative to its recent volatility. The technical resistance identified at 8.03 euros was breached during the day, a signal closely monitored by market operators.
Upcoming Financial Milestones
Several financial deadlines are looming in the coming weeks for the biotech specializing in liver and metabolic diseases. The annual 2025 revenue will be announced on February 26, exactly one week from now. This event will be followed by the publication of the annual 2025 results, expected on April 2. These two publications will allow for an assessment of GENFIT's commercial and financial trajectory over the past year, during which the stock more than doubled with an increase of 116%. Beyond these milestones, the general meeting is scheduled for June 15, and the results for the first half of 2026 will be unveiled on September 29. The stock's beta, measured at 0.13, reflects a very low correlation with the fluctuations of the reference index, a common characteristic of biotechnological values whose evolution depends more on specific catalysts – clinical advancements, partnerships, or regulatory publications – than on the general stock market conditions. The monthly volatility stands at 15.52%, a level consistent with the acceleration observed in recent weeks.
